BlackRock’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-14,567
| Closed | -$131K | – | 3906 |
|
|
2016
Q3 | $131K | Sell |
14,567
-4,278
| -23% | -$30.4K | ﹤0.01% | 2437 |
|
|
2016
Q2 | $101K | Buy |
18,845
+12,894
| +217% | +$66.1K | ﹤0.01% | 2538 |
|
|
2016
Q1 | $27K | Buy |
5,951
+2,976
| +100% | +$12K | ﹤0.01% | 2712 |
|
|
2015
Q4 | $16K | Buy |
2,975
+105
| +4% | +$609 | ﹤0.01% | 2698 |
|
|
2015
Q3 | $17K | Buy |
2,870
+557
| +24% | +$6.83K | ﹤0.01% | 2498 |
|
|
2015
Q2 | $36K | Buy |
2,313
+204
| +10% | +$2.48K | ﹤0.01% | 2133 |
|
|
2015
Q1 | $23K | Buy |
2,109
+130
| +7% | +$1.33K | ﹤0.01% | 2313 |
|
|
2014
Q4 | $20K | Hold |
1,979
| – | – | ﹤0.01% | 2391 |
|
|
2014
Q3 | $19K | Hold |
1,979
| – | – | ﹤0.01% | 2383 |
|
|
2014
Q2 | $23K | Hold |
1,979
| – | – | ﹤0.01% | 2314 |
|
|
2014
Q1 | $20K | Hold |
1,979
| – | – | ﹤0.01% | 2378 |
|
|
2013
Q4 | $26K | Hold |
1,979
| – | – | ﹤0.01% | 2246 |
|
|
2013
Q3 | $30K | Hold |
1,979
| – | – | ﹤0.01% | 2072 |
|
|
2013
Q2 | $19K | Buy |
+1,979
| New | +$13.4K | ﹤0.01% | 2341 |
|
BlackRock's RPTP Position: Q4 2016 in Review
BlackRock sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 14,567 shares — an estimated $131K sold.
BlackRock first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $131K in Q3 2016. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- BlackRock reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- BlackRock sold 14,567 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $131K.
- BlackRock first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- BlackRock's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $131K in Q3 2016.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on BlackRock's 13F filing for Q4 2016, filed 10 Feb 2017.